Search
"Therefore, PICC catheter is worthy of application and promotion in hematological diseases" Li et al (2021).

PICC use in hematological disease

Abstract:

Objective: The aim of the study was to investigate the efficacy analysis and hemodynamic changes of hematological system diseases after peripherally inserted central catheter (PICC) chemotherapy.

Patients and methods: From March 2017 to March 2020, patients with hematological diseases who received chemotherapy in our hospital were selected. The experimental group consisted of 80 patients with PICC, and the control group consisted of 70 patients with routine intravenous injection. The indwelling time, prevalence rate of adverse reactions, hemodynamic indicators before and after chemotherapy and compliance of patients in the two groups were compared.

Results: The longest time and average time of indwelling catheter in experimental group were significantly higher than those in control group (p<0.05). The total prevalence rate of adverse reactions in experimental group (3.75%) was significantly lower than that in control group (20%) (p<0.05). The compliance of patients with PICC in experimental group was significantly better than that of patients with superficial intravenous injection in control group. There was no significant difference in hemodynamic indicators between experimental group and control group before and after chemotherapy (p>0.05). There was significant difference in high-shear whole blood indicators, low-shear whole blood viscosity and high-shear whole blood viscosity after chemotherapy (p<0.05), while there was no significant difference in changes of other hemodynamic indicators (p>0.05) or in hemorheological indicators between the two groups after chemotherapy (p>0.05).

Conclusions: The total prevalence of adverse reactions in hematological diseases by PICC infusion is lower than that by superficial vein infusion, and the catheter has no significant influence on hemodynamic indicators in patients. Therefore, PICC catheter is worthy of application and promotion in hematological diseases.


Reference:

Li P, Sun X, Tang J, Wei CS, Zhao J. Efficacy analysis and hemodynamic changes of hematological system diseases after PICC chemotherapy. Eur Rev Med Pharmacol Sci. 2021 Nov;25(21):6566-6572. doi: 10.26355/eurrev_202111_27099. PMID: 34787858.